As the Managing Partner at Ax-S Pharma, LLC, Jess Rabourn leverages over a decade of expertise in the regulation and practice of pre-market medicine access to drive innovative solutions in the pharmaceutical landscape. With a pioneering spirit, Jess founded the first 501(c)(3) organization dedicated exclusively...
As the Managing Partner at Ax-S Pharma, LLC, Jess Rabourn leverages over a decade of expertise in the regulation and practice of pre-market medicine access to drive innovative solutions in the pharmaceutical landscape. With a pioneering spirit, Jess founded the first 501(c)(3) organization dedicated exclusively to this cause in 2011, setting a precedent for expanded access initiatives. At Ax-S Pharma, Jess leads a team of specialists in specialty consulting, providing invaluable insights to pharmaceutical companies, clinical researchers, and non-profit organizations navigating the complexities of Expanded Access clinical trials for investigational drugs.
One of Jess's key projects includes the development and implementation of large-scale, data-generating Expanded Access programs through WideTrial, Inc., a commercial venture that purchases investigational products directly from manufacturers. This initiative not only enhances patient access to potentially life-saving treatments but also generates critical data that informs drug development and regulatory strategies. Jess's deep understanding of Good Clinical Practice (GCP) and drug development processes enables him to craft tailored strategies that align with the unique needs of each client, ensuring compliance while maximizing patient benefit.
With a robust skill set that spans business development, consulting, and alternative investments, Jess is adept at navigating the intersection of life sciences and finance. His strategic insights into hedge funds and fixed income investments further bolster his ability to guide clients in making informed decisions that optimize their portfolios and enhance their operational efficiencies. Through his leadership at Ax-S Pharma, Jess continues to champion the cause of expanded access, advocating for a healthcare landscape where more patients can benefit from groundbreaking therapies.
